恩替卡韦治疗失代偿期乙肝肝硬化患者的远期评价

Long-Term Evaluation of Entecavir in the Treatment of Patients With Decompensated Hepatitis B Cirrhosis

目的探究失代偿期乙肝肝硬化患者接受恩替卡韦治疗的价值。方法选取失代偿期乙肝肝硬化患者60例,根据其治疗方案差异分组,2组均接受常规保肝、护肝治疗,对照组同时接受拉米夫定治疗,实验组同时接受恩替卡韦治疗,对比2组失代偿期乙肝肝硬化患者治疗结果的差异性。结果 2组失代偿期乙肝肝硬化患者,其肝功能指标(TBIL、ALB、ALT)水平均较治疗前改善(P<0.05),2组治疗前后肝功能指标水平、不良反应发生率等相比,差异无统计学意义(P>0.05)。结论失代偿期乙肝肝硬化接受恩替卡韦治疗,具有较高的安全性和有效性。

Objective To explore the value of entecavir for patients with hepatitis B cirrhosis in decompensation. Methods 60 patients with hepatitis B cirrhosis were selected for decompensation, and the 2 groups were treated with conventional liver protection and liver protection according to the differences in the treatment scheme. The control group was treated with lamivudine, and the experimental group received entecavir at the same time. The difference in the outcome of the 2 groups of patients with hepatitis B cirrhosis was compared. Results The level of liver function index（TBIL, ALB, ALT） in the 2 groups of patients with decompensated hepatitis B cirrhosis was better than that before treatment（P〈0.05）. There was no significant difference in the level of liver function index and the incidence of adverse reaction between the 2 groups before and after treatment（P〈0.05）. Conclusion In the period of decompensation, hepatitis B liver cirrhosis is treated with entecavir, which has high safety and effectiveness.